Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico

Value in Health Regional Issues

Volumn 1, Issue 2, 2012, Pages 211-217

  Rely, Kely ^a   Galindo Suárez, Rosa María ^b   Alexandre, Pierre K ^c   García García, Erika Gabriela ^b   Muciño Ortega, Emilio ^b   Salinas Escudero, Guillermo ^d   Martínez Valverde, Silvia ^d  

^a CEAHealthTech   (Mexico)

^b PFIZER INC   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Cost effectiveness; Immunosuppression; Markov model; Renal transplant; Sirolimus

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; GRAFT RECIPIENT; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MATHEMATICAL MODEL; MEXICO; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

EID: 84870935836     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.09.013     Document Type: Article

References (53)

1. Grassmann A, Gioberge S, Moeller S, Brown G. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 2006; 30: 895-897.
2. Meguid El Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005, 365:331-340.
3. Arredondo A., Burke T.A., Carides G.W., et al. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico. Rev Invest Clin 2005, 57(3):399-405.
4. Brien H., Garcia H., Garcia G., et al. Epidemiología de la insuficiencia renal crónica en Jalisco. Boletín Colegio Jalisciense Nefrología 2001, 5:6-8.
5. Fiebiger W., Mitterbauer C., Oberbauer R. Health-related quality of life outcomes after kidney transplantation. Health Qual Life Outcomes 2004, 2:2.
6. Joseph J.T., Baines L.S., Morris M.C., Jindal R.M. Quality of life after kidney and pancreas transplantation: a review. Am J Kidney Dis 2003, 42:431-445.
7. Winkelmayer W.C., Weinstein M.C., Mittleman M.A., et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002, 22:417-430.
8. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
9. Woodroffe R., Yao G.L., Meads C., et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005, 9:1-4.
10. Prieto I, Bhattacharyya Samir K, Divino J.C, Paniagua R. Costs of treating ESRD patients with various dialysis therapies in Mexico. iHEA 2007 6th World Congress: explorations in health economics paper. Available from: [Accessed September 20, 2012]. http://ssrn.com/abstract=992072.
11. Irish W., Sherrill B., Brennan D.C., et al. Three-year post transplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation 2003, 76:1686-1690.
12. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000, 69:834-841.
13. Kaplan B., Schold J.D., Meier-Kriesche H.U. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003, 14:2980-2984.
14. De Mattos A.M., Olyaei A.J., Bennett W.M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000, 35:333-346.
15. Henry M.L. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999, 13:209-220.
16. Morales J.M., Wramner L., Kreis H., et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002, 2:436-442.
17. Alberú J., Urrea E.M. Immunosuppression for kidney transplant recipients: current strategies. Rev Invest Clín 2005, 57. 278.
18. Mihatsch M.J., Kyo M., Morozumi K., et al. The side-effects of cyclosporine-A and tacrolimus. Clin Nephrol 1998, 49:356-363.
19. Podbielski J., Schoenberg L. Use of sirolimus in kidney transplantation. Prog Transplant 2001, 11:29-32.
20. Morelon E., Mamzer-Bruneel M.F., Peraldi M.N., et al. Sirolimus: a new promising immunosuppressive drug: towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 2001, 16:18-20.
21. Kreis H., Oberbauer R., Campistol J.M., et al. Long-term benefits with sirolimus-based therapy following early cyclosporine withdrawal. J Am Soc Nephrol 2004, 15:809-817.
22. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005, 18:22-28.
23. Mota A., Arias M., Taskinen E.I., et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004, 4:953-961.
24. Campistol J.M., Eris J., Oberbauer R., et al. The Rapamune Maintenance Regimen (RMR) Study Group. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006, 17:581-589.
25. Citterlo F., Scata M.C., Violi P., et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003, 35:1292-1294.
26. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004, 4:1869-1875.
27. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmaeconomics 1998, 13:397-409.
28. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338.
29. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
30. Lebranchu Y., Thierry A., Toupance O., et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009, 9:1115-1123.
31. Chisholm M.A. Impact of clinical pharmacy services on renal transplant patients compliance with immunosuppressive medications. Clin Transpl 2001, 15:330-336.
32. Morales J.M., Domínguez-Gil B. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hyper 2005, 23:1609-1616.
33. Groth C.G., Backman L., Morales J.M., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999, 67:1036-1042.
34. Kreis H., Cisterne J.M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000, 69:1252-1260.
35. Hasegawa T, Imai H, Miki S. Cost evaluation of Basiliximab treatment for renal transplant patients in Japan. Pharmacoeconomics 2003;21:791-806.
36. Campbell S, Mc Donald S, Chang S et al. ANZDATA Registry Report 2007; 8:1-22.
37. Morton R.L., Howard K., Webster A.C., et al. The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant 2009, 24:2258-2269.
38. Arredondo A, Rangel R, de Icaza E. Costo-efectividad de intervenciones para insuficiencia renal crónica terminal. Rev. Saúde Pública 1998;32:556-65.
39. Instituto Mexicano del Seguro Social (IMSS). Portal de Transparencia. IMSS va a comprar, IMSS compró. Periodo Enero-Junio 2012: Disponible en: [Accesado Agosto 2012]. http://transparencia.imss.gob.mx/trnsp/ncompro.aspx?c=1.
40. Laupacis A., Keown P., Pus N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996, 50:235-242.
41. Consejo de Salubridad General. Guía para la conducción de estudios de evaluación económica para la actualización del Cuadro Básico de Insumos del Sector Salud en México. 2008. Available from: [Accessed September 20, 2012]. http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/GUxA_EVAL_ECON25082008_2_ech.pdf.
42. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Available from: [Accessed September 20, 2012]. http://www.who.int/choice/costs/CER_thresholds/en/index.html.
43. García P.M., Reyes H.M., Viniegra V.L., et al. Las múltiples facetas de la investigación en Salud 2001, IMSS, México, DF.
44. Keane H. Advances in slowing the progress of diabetic nephropathy. Patient Care 2001, 30:28-41.
45. Rodríguez M. Características epidemiológicas de pacientes con diabetes-IRC en el Estado de México. Rev Med IMS 2003, 41. 383-59.
46. Cusumano A.M., Di Gioia C., Hermida O., Lavorato C. on behalf of the Latin American Registry of Dialysis and Renal Transplantation. The Latin American Dialysis and Renal Transplantation Registry annual report 2002. Kidney Int Suppl 2005, 97(Suppl):S46-S52.
47. McEwan P., Dixon S., Baboolal K., et al. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics 2006, 24:67-79.
48. Kahan B.D., Rapamune U.S. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicenter study. Lancet 2000, 356:194-202. Study Group.
49. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271-280. Rapamune Global Study Group.
50. Johnson R.W.G., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001, 72:777-786.
51. Oberbauer R., Kreis H., Johnson R.W.G., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen study. Transplantation 2003, 76:364-370.
52. McEwan P., Baboolal K., Conway P., Currie C.J. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther 2007, 27:1834-1846.
53. Gordois A., Nobes M., Tohhey M., Russ G. Cost-effectiveness of sirólimus therapy with early cyclosporine withdrawal vs. long-term cyclosporine therapy in Australia. Clin Transplant 2006, 20:526-536.